Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine sulfate versus chloroquine phosphate for mild to moderate COVID-19
ChiCTR2000029899Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine sulfate with Chloroquine phosphate (2 arms). Primary endpoint: Time to clinical recovery. Started Feb 2020; status: recruiting.
02
Drugs
hydroxychloroquinechloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029899.